Full Text Journal Articles in
Journal Gynecol Oncol

Advertisement

Find full text journal articles






Corrigendum to "Beyond Sedlis-A novel histology-specific nomogram for predicting cervical cancer recurrence risk: An NRG/GOG ancillary analysis" [Gynecologic Oncology 162 (2021) 532-538].

Kimberly Levinson, Anna L Beavis, Christopher Purdy, Anne F Rositch, Akila Viswanathan, Aaron H Wolfson, Michael G Kelly, Krishnansu S Tewari, Leah McNally, Saketh R Guntupalli, Omar Ragab, Yi-Chun Lee, David S Miller, Warner K Huh, Kelly J Wilkinson, Nicola M Spirtos, Linda Van Le, Yovanni Casablanca, Laura L Holman, Steven E Waggoner, Amanda N Fader,

Gynecol Oncol (Gynecologic oncology)
[2021, :]

Cited: 0 times

View full text PDF listing >>



Menopausal symptoms in epithelial ovarian cancer survivors: a GINECO VIVROVAIRE2 study.

F Gernier, A Gompel, C Rousset-Jablonski, E Kalbacher, A Floquet, D Berton-Rigaud, O Tredan, J Alexandre, P Follana, A Zannetti, N Dohollou, J-M Grellard, B Clarisse, I Licaj, D Ahmed-Lecheheb, R Fauvet, P Pautier, F Joly,

<h4>Objective</h4>We have previously shown that epithelial ovarian cancer (EOC) and its treatments have negative effects on long-term quality of life (QoL) and fatigue. The present multicenter study investigated the main menopausal symptoms and gynecological management of EOC survivors (EOCS).<h4>Methods</h4>166 patients with relapse-free ≥3 years after the end of treatment attended a ... Read more >>

Gynecol Oncol (Gynecologic oncology)
[2021, :]

Cited: 0 times

View full text PDF listing >>



Advertisement

Results of TRIO-14, a phase II, multicenter, randomized, placebo-controlled trial of carboplatin-paclitaxel versus carboplatin-paclitaxel-ganitumab in newly diagnosed epithelial ovarian cancer.

G E Konecny, A E Wahner Hendrickson, T M Davidson, B J Winterhoff, S Ma, S Mahner, J Sehouli, P A Fasching, G Feisel-Schwickardi, M Poelcher, L D Roman, A Rody, B Y Karlan, S A Mullany, H Chen, I L Ray-Coquard, D M Provencher, A Yachnin, P H Cottu, J A Glaspy, P Haluska, D J Slamon,

<h4>Purpose</h4>Insulin-like growth factor (IGF) signaling is implicated in pathogenesis and chemotherapy resistance of epithelial ovarian cancer (EOC). We explored efficacy and safety of adding ganitumab, a monoclonal antibody targeting IGF-1R, to carboplatin/paclitaxel (CP) chemotherapy in patients with primary EOC.<h4>Design</h4>Patients were randomly assigned to receive CP/ganitumab (18 mg/kg q3w) or CP/placebo for ... Read more >>

Gynecol Oncol (Gynecologic oncology)
[2021, :]

Cited: 0 times

View full text PDF listing >>



Phase 2 study of anastrozole in rare cohorts of patients with estrogen receptor/progesterone receptor positive leiomyosarcomas and carcinosarcomas of the uterine corpus: The PARAGON trial (ANZGOG 0903).

R J Edmondson, R L O'Connell, S Banerjee, L Mileshkin, P Sykes, P Beale, A Fisher, A Bonaventura, D Millan, S Nottley, C Benson, A Hamilton, K Sjoquist, L Alexander, C Kelly, K Carty, L Divers, N Bradshaw, M Friedlander, ,

<h4>Background</h4>Aromatase inhibitors have been used empirically to treat a subset of patients with hormone receptor positive uterine leiomyosarcomas(LMS) and carcinosarcomas (UCS) mainly supported by retrospective data. We evaluated the activity of anastrozole in two rare cohorts; patients with recurrent/metastatic LMS and UCS enrolled in PARAGON, a basket trial of anastrozole ... Read more >>

Gynecol Oncol (Gynecologic oncology)
[2021, :]

Cited: 0 times

View full text PDF listing >>



An open-label phase I dose-escalation study of the safety and pharmacokinetics of DMUC4064A in patients with platinum-resistant ovarian cancer.

Joyce Liu, Howard Burris, Judy S Wang, Lisa Barroilhet, Martin Gutierrez, Yulei Wang, Anjali Vaze, Renee Commerford, Stephanie Royer-Joo, Voleak Choeurng, Eric Humke, Kathleen Moore,

<h4>Objectives</h4>MUC16 is overexpressed in the majority of human epithelial ovarian cancers (OC). DMUC4064A is a humanized anti-MUC16 monoclonal antibody conjugated to the microtubule-disrupting agent monomethyl auristatin E. This trial assessed the safety, tolerability, pharmacokinetics, and preliminary activity of DMUC4064A in patients with platinum-resistant OC.<h4>Methods</h4>DMUC4064A was administered once every 3 weeks to ... Read more >>

Gynecol Oncol (Gynecologic oncology)
[2021, :]

Cited: 0 times

View full text PDF listing >>



Combination ATR and PARP Inhibitor (CAPRI): A phase 2 study of ceralasertib plus olaparib in patients with recurrent, platinum-resistant epithelial ovarian cancer.

Payal D Shah, Stephanie L Wethington, Cheyenne Pagan, Nawar Latif, Janos Tanyi, Lainie P Martin, Mark Morgan, Robert A Burger, Ashley Haggerty, Haley Zarrin, Diego Rodriguez, Susan Domchek, Ronny Drapkin, Ie-Ming Shih, Simon A Smith, Emma Dean, Stéphanie Gaillard, Deborah Armstrong, Drew A Torigian, Wei-Ting Hwang, Robert Giuntoli, Fiona Simpkins,

<h4>Objective</h4>Platinum-resistant, high-grade serous ovarian cancer (HGSOC) has limited treatment options. Preclinical data suggest that poly(ADP-ribose) polymerase inhibitors (PARPi) and ataxia telangiectasia and Rad3-related kinase inhibitors (ATRi) are synergistic. CAPRI (NCT03462342) is an investigator-initiated study of olaparib plus ceralasertib in recurrent HGSOC. Herein, we present results from the platinum-resistant cohort.<h4>Methods</h4>A Simon ... Read more >>

Gynecol Oncol (Gynecologic oncology)
[2021, :]

Cited: 0 times

View full text PDF listing >>



The urban-rural gap: Disparities in ovarian cancer survival among patients treated in tertiary centers.

Kiran H Clair, Robert E Bristow,

Gynecol Oncol (Gynecologic oncology)
[2021, 163(1):3-4]

Cited: 0 times

View full text PDF listing >>



Corrigendum to: Postoperative outcomes of primary and interval cytoreductive surgery for advanced ovarian cancer registered in the Dutch Gynecological Oncology Audit (DGOA) [Gynecologic Oncology Volume 162, Issue 2, August 2021, Pages 331-338].

N M S Baldewpersad Tewarie, W J van Driel, M van Ham, M W Wouters, R Kruitwagen, ,

Gynecol Oncol (Gynecologic oncology)
[2021, :]

Cited: 0 times

View full text PDF listing >>



Early prediction of post-molar gestational trophoblastic neoplasia and resistance to methotrexate, based on a single serum human chorionic gonadotropin measurement.

Yvonne M Hoeijmakers, Yalck K Eysbouts, Leon F A G Massuger, Rana Dandis, Joanna Inthout, N E van Trommel, Petronella B Ottevanger, Chris M G Thomas, Fred C G J Sweep,

<h4>Background</h4>Clinicians are unable to provide individualized counseling regarding risk of progression for patients with a complete hydatidiform mole (CHM). We developed nomograms enabling early prediction of post-molar gestational trophoblastic neoplasia (GTN) and resistance to methotrexate (MTX) based on a single serum human chorion gonadotropin (hCG) measurement.<h4>Methods</h4>We generated two nomograms with ... Read more >>

Gynecol Oncol (Gynecologic oncology)
[2021, :]

Cited: 0 times

View full text PDF listing >>



MicroRNA profiling in a case-control study of African American women with uterine serous carcinoma.

Larissa Lee, Brooke Howitt, Teresa Cheng, Martin King, Konrad Stawiski, Wojciech Fendler, Dipanjan Chowdhury, Ursula Matulonis, Panagiotis A Konstantinopoulos,

<h4>Objective</h4>Uterine serous carcinoma (USC) is an aggressive subtype of endometrial cancer associated with worse survival outcomes in African American (AA) patients. This study evaluated tumor miRNA expression by race, clinical and tumor characteristics, and survival outcomes.<h4>Methods</h4>FFPE tumor tissue from hysterectomy specimens was identified for 29 AA cases. Case matching was ... Read more >>

Gynecol Oncol (Gynecologic oncology)
[2021, :]

Cited: 0 times

View full text PDF listing >>



Histological patterns and intra-tumor heterogeneity as prognostication tools in high grade serous ovarian cancers.

Eros Azzalini, Renzo Barbazza, Giorgio Stanta, Giorgio Giorda, Lucia Bortot, Michele Bartoletti, Fabio Puglisi, Vincenzo Canzonieri, Serena Bonin,

<h4>Objective</h4>High grade serous ovarian carcinoma (HGSOC) is the most common type of malignant ovarian neoplasm and the main cause of ovarian cancer related deaths worldwide. Although novel biomarkers such as homologous recombination deficiency testing have been implemented into the clinical decision-making algorithm since diagnosis, morphological classification and immunohistochemistry analysis are ... Read more >>

Gynecol Oncol (Gynecologic oncology)
[2021, :]

Cited: 0 times

View full text PDF listing >>



Development and validation of a comprehensive clinical risk-scoring model for prediction of overall survival in patients with endometrioid endometrial carcinoma.

Mariam M AlHilli, Lisa Rybicki, Caitlin Carr, Meng Yao, Sudha Amarnath, Roberto Vargas, Robert Debernardo, Chad Michener, Peter G Rose,

<h4>Objective</h4>To develop and validate a comprehensive overall survival (OS) risk-scoring model in women with endometrioid endometrial cancer (EC).<h4>Methods</h4>Patients with EC diagnosed from 2004 to 2013 were identified through the National Cancer Database (NCDB). Patients with known lymphovascular space invasion (LVSI) status who were treated surgically (with or without adjuvant therapy) ... Read more >>

Gynecol Oncol (Gynecologic oncology)
[2021, :]

Cited: 0 times

View full text PDF listing >>



Characterization of patients with long-term responses to rucaparib treatment in recurrent ovarian cancer.

Elizabeth M Swisher, Rebecca S Kristeleit, Amit M Oza, Anna V Tinker, Isabelle Ray-Coquard, Ana Oaknin, Robert L Coleman, Howard A Burris, Carol Aghajanian, David M O'Malley, Alexandra Leary, Stephen Welch, Diane Provencher, Geoffrey I Shapiro, Lee-May Chen, Ronnie Shapira-Frommer, Scott H Kaufmann, Sandra Goble, Lara Maloney, Tanya Kwan, Kevin K Lin, Iain A McNeish,

<h4>Objective</h4>To describe molecular and clinical characteristics of patients with high-grade recurrent ovarian carcinoma (HGOC) who had long-term responses to the poly(ADP-ribose) polymerase (PARP) inhibitor rucaparib.<h4>Methods</h4>This post hoc analysis pooled patients from Study 10 (NCT01482715; Parts 2A and 2B; n = 54) and ARIEL2 (NCT01891344; Parts 1 and 2; n = 491). Patients with investigator-assessed ... Read more >>

Gynecol Oncol (Gynecologic oncology)
[2021, :]

Cited: 0 times

View full text PDF listing >>



Incidence and treatment outcomes of ovarian sarcoma compared to epithelial ovarian cancer from the national cancer registry.

Hyeong In Ha, Sang-Hyun Cho, Jiwon Lim, Yeon Jee Lee, Chong Woo Yoo, Young-Joo Won, Myong Cheol Lim,

<h4>Purpose</h4>To investigate the incidence and survival outcomes of primary ovarian sarcoma compared to those of epithelial ovarian cancer.<h4>Methods</h4>Data on primary ovarian sarcoma patients (n = 1361) and epithelial ovarian cancer patients (n = 30,366) between 1999 and 2017 were obtained from the Korea Central Cancer Registry, and their respective age-standardized incidence rate (ASR) and ... Read more >>

Gynecol Oncol (Gynecologic oncology)
[2021, :]

Cited: 0 times

View full text PDF listing >>



Corrigendum to 'A state-wide population-based evaluation of cervical cancers arising during opportunistic screening in the United States' [Gynecologic Oncology 159 (2020) 344-353].

Rebecca Landy, Christopher Mathews, Michael Robertson, Charles L Wiggins, Yolanda J McDonald, Daniel W Goldberg, Isabel C Scarinci, Jack Cuzick, Peter D Sasieni, Cosette M Wheeler, ,

Gynecol Oncol (Gynecologic oncology)
[2021, :]

Cited: 0 times

View full text PDF listing >>



Prognostic impact of mismatch repair deficiency in high- and low-intermediate-risk, early-stage endometrial cancer following vaginal brachytherapy.

Jessie Y Li, Henry S Park, Gloria S Huang, Melissa R Young, Elena Ratner, Alessandro Santin, Shari Damast,

<h4>Objectives</h4>To examine the impact of mismatch repair (MMR) status on prognosis among patients with high- and low-intermediate-risk endometrioid endometrial cancer (EEC) treated with vaginal brachytherapy (VBT).<h4>Materials/methods</h4>198 stage I-II EEC patients with known MMR status treated with adjuvant VBT were identified. Both low-intermediate (LIR) and high-intermediate-risk (HIR) patients were included. Clinical ... Read more >>

Gynecol Oncol (Gynecologic oncology)
[2021, :]

Cited: 0 times

View full text PDF listing >>



Fertility-sparing surgery and fertility preservation in cervical cancer: The desire for parenthood, reproductive and obstetric outcomes.

R C J van der Plas, A M E Bos, I M Jürgenliemk-Schulz, C G Gerestein, R P Zweemer,

<h4>Objective</h4>To evaluate the desire for parenthood and reproductive outcomes of young cervical cancer survivors who underwent fertility-sparing surgery or fertility preservation procedures for invasive cervical cancer.<h4>Methods</h4>All women <45 years who underwent fertility-sparing treatment for invasive cervical cancer in a tertiary referral center in the Netherlands between January 2009 and January 2020 ... Read more >>

Gynecol Oncol (Gynecologic oncology)
[2021, :]

Cited: 0 times

View full text PDF listing >>



Parity, menopausal hormone therapy, and risk of ovarian granulosa cell tumor - A population-based case-control study.

Saara Bryk, Sushmita Katuwal, Ulla-Maija Haltia, Johanna Tapper, Juha S Tapanainen, Eero Pukkala,

<h4>Objective</h4>Adult-type ovarian granulosa cell tumors (AGCTs) are hormonally active neoplasms with limited epidemiological data available. We evaluated the effect of parity and postmenopausal hormone therapy (HT) use on the risk of AGCT in a population-based case-control setting.<h4>Methods</h4>We identified all women diagnosed with AGCT during 1994-2015 (n = 505) from the Finnish Cancer ... Read more >>

Gynecol Oncol (Gynecologic oncology)
[2021, :]

Cited: 0 times

View full text PDF listing >>



Patterns of care and outcomes of radiotherapy or hormone therapy in patients with medically inoperable endometrial adenocarcinoma.

Leonid B Reshko, Jeremy T Gaskins, Abbas Rattani, Alyssa A Farley, Grant W McKenzie, Scott R Silva,

<h4>Objective</h4>The optimal treatment for medically inoperable endometrioid endometrial adenocarcinoma is unknown. The goal of this study was to evaluate the patterns of care and efficacy of radiotherapy (RT) or hormone therapy (HT) in the treatment of these patients.<h4>Methods</h4>We performed a query of the National Cancer Database (NCDB) of patients with ... Read more >>

Gynecol Oncol (Gynecologic oncology)
[2021, :]

Cited: 0 times

View full text PDF listing >>



Clinical outcome in patients with primary epithelial ovarian cancer and germline BRCA1/2-mutation - real life data.

Beyhan Ataseven, Denise Tripon, Richard Schwameis, Philipp Harter, Kerstin Rhiem, Stephanie Schneider, Sebastian Heikaus, Thaïs Baert, Alesina Pier Francesco, Florian Heitz, Alexander Traut, Harald-Thomas Groeben, Rita Schmutzler, Andreas du Bois,

<h4>Background</h4>We evaluated the clinical impact of germline (g)BRCA1/2-mutation on initial disease presentation, surgical implications, surgical morbidity and survival in patients with advanced epithelial ovarian cancer (EOC) undergoing debulking surgery (DS).<h4>Methods</h4>Data of all consecutive EOC patients with stage III/IV, high-grade serous disease and known gBRCA1/2 status (gBRCA; non-gBRCA), who underwent DS ... Read more >>

Gynecol Oncol (Gynecologic oncology)
[2021, :]

Cited: 0 times

View full text PDF listing >>



Assessment of immune biomarkers and establishing a triple negative phenotype in gynecologic cancers.

G Contos, Y Baca, J Xiu, J Brown, R Holloway, W M Korn, T J Herzog, N Jones, I Winer,

<h4>Objective</h4>Immuno-oncology (IO) has rapidly evolved, with many IO therapies either approved or under investigation for multiple malignancies. Biomarkers exist that can predict response to IO therapies including PD-L1 expression, microsatellite instability (MSI), and total mutation burden (TMB). This paper serves to analyze the presence of these biomarkers across gynecologic cancers.<h4>Methods</h4>A ... Read more >>

Gynecol Oncol (Gynecologic oncology)
[2021, :]

Cited: 0 times

View full text PDF listing >>



Practice patterns and survival in FIGO 2009 stage 3B endometrial cancer.

Jessica Jou, Lindsey Charo, Marianne Hom-Tedla, Katherine Coakley, Pratibha Binder, Cheryl Saenz, Ramez N Eskander, Michael McHale, Steven Plaxe,

<h4>Objective</h4>To describe the practice patterns and outcomes of patients with stage 3B endometrial cancer.<h4>Methods</h4>We queried the National Cancer Database for all surgically staged, stage 3 patients between 2012 and 2016. Patients who received any pre-operative therapy were excluded. Demographics, tumor factors, and adjuvant therapy for the stage 3 substages were ... Read more >>

Gynecol Oncol (Gynecologic oncology)
[2021, :]

Cited: 0 times

View full text PDF listing >>



Ultrasonographic evaluation of ovarian mass for predicting malignancy in pregnant women.

Se Jin Lee, Young-Han Kim, Mi-Young Lee, Hyun Sun Ko, Soo-Young Oh, Hyun-Joo Seol, Jong Woon Kim, Ki Hoon Ahn, Sunghun Na, Won Joon Seong, Hee Seung Kim, Chan-Wook Park, Joong Shin Park, Jong Kwan Jun, Hye-Sung Won, Moon Young Kim, Han Sung Hwang, Seung Mi Lee,

<h4>Objective</h4>The purpose of this study is to compare ultrasonographic ovarian mass scoring systems in pregnant women.<h4>Study design</h4>This multicenter study included women with an ovarian mass during pregnancy who were evaluated using ultrasound and underwent surgery in 11 referral hospitals. The ovarian mass was evaluated and scored using three different scoring ... Read more >>

Gynecol Oncol (Gynecologic oncology)
[2021, :]

Cited: 0 times

View full text PDF listing >>



Antihypertensive medication use and ovarian cancer survival.

Tianyi Huang, Mary K Townsend, Robert L Dood, Anil K Sood, Shelley S Tworoger,

<h4>Objective</h4>Although experimental models suggest that use of beta-blockers, a common antihypertensive agent, may improve survival in ovarian cancer patients, results from clinical studies have been mixed.<h4>Methods</h4>We evaluated the associations of pre-diagnostic (n = 950) and post-diagnostic (n = 743) use of antihypertensive medications with survival among patients with invasive, epithelial ovarian cancer in the ... Read more >>

Gynecol Oncol (Gynecologic oncology)
[2021, :]

Cited: 0 times

View full text PDF listing >>



Obesity and altered angiogenic-related gene expression in endometrial cancer.

Lauren Patterson Cobb, Sharareh Siamakpour-Reihani, Dadong Zhang, Xiaodi Qin, Kouros Owzar, Chunxiao Zhou, Thomas P Conrads, G Larry Maxwell, Kathleen M Darcy, Nicholas W Bateman, Tracy Litzi, Victoria Bae-Jump, Angeles Alvarez Secord,

<h4>Objectives</h4>Evaluate association between obesity and angiogenic-related gene expression in endometrial cancer (EC). Evaluate interaction between diet and metformin on angiogenic-related gene expression.<h4>Methods</h4>We evaluated the association between 168 human angiogenic-related genes and body mass index (BMI) in the TCGA Uterine Corpus Endometrial Carcinoma cohort (endometrioid endometrial cancer (EEC) cohort n = 290, and ... Read more >>

Gynecol Oncol (Gynecologic oncology)
[2021, :]

Cited: 0 times

View full text PDF listing >>



Advertisement


Disclaimer

2.0361 s